Analysis Kobayashi Pharmaceutical Co., Ltd. (4967)
6/1/2024
Analysis of Kobayashi Pharmaceutical Co., Ltd. (4967)
Kobayashi Pharmaceutical Co., Ltd. (4967) has been showing some fluctuations in its stock price recently. The Relative Strength Index (RSI) values have been hovering around 50, indicating a balanced market sentiment. The Moving Average Convergence Divergence (MACD) indicator has been fluctuating around the zero line, suggesting indecision among traders.The stock price has been moving within a range, with the Simple Moving Average (SMA) and Exponential Moving Average (EMA) values staying close to each other. The Weighted Moving Average (WMA) has been slightly lower, indicating some downward pressure.
Overall, Kobayashi Pharmaceutical Co., Ltd. seems to be experiencing a period of consolidation and uncertainty in the market. Traders may want to wait for a clearer trend to emerge before making any significant trading decisions.
Earnings
The company's results for the most recent quarter, ending on April 30, 2025, have not been provided at this time. The previous quarter's results, ending on February 27, 2025, were handled by the Transfer Agent. The quarter before that, ending on January 31, 2025, had results released After Hours. The results for the quarter ending on October 31, 2024, were not provided at the time. However, for the quarter ending on August 1, 2024, the company reported an earnings per share (EPS) estimate of 1.32.Main Statystic ðŸ§
The data provided includes financials, stock statistics, valuation metrics, stock price summary, and dividends and splits information for a specific company.In terms of financials, the company has strong operating cash flow and levered free cash flow, with a positive current ratio. The profit margin and operating margin are also healthy, indicating efficient operations. The company's fiscal year ends in September 2023, and it has shown a positive return on assets and return on equity.
Looking at stock statistics, the company has a low short ratio and a significant percentage of shares held by institutions. The stock price has fluctuated between a fifty-two-week low and high, with a positive change over the period.
Valuation metrics show a relatively high PEG ratio and price-to-earnings ratios, along with other valuation multiples. The market capitalization and enterprise value are also provided.
The stock price summary includes beta, moving averages, and the range of prices over the past year.
Lastly, dividends and splits information shows the company's dividend history, payout ratio, and dividend yield metrics. The company has a regular dividend payment schedule and has undergone a stock split in the past.
Income statement 💸
Here are the revenue figures for the company over the past four fiscal years:1. Fiscal Year 2023: Sales of $383,285,000,000
2. Fiscal Year 2022: Sales of $394,328,000,000
3. Fiscal Year 2021: Sales of $365,817,000,000
4. Fiscal Year 2020: Sales of $274,515,000,000
From these figures, we can observe the following trends:
- The company experienced a significant increase in sales from 2020 to 2022, followed by a slight decrease in 2023.
- Despite the decrease in 2023, the sales figures remain higher compared to 2020.
- Overall, there is a positive trend in revenue growth over the four-year period, indicating a general upward trajectory in the company's sales performance.
Balance Sheet
These are balance sheets. Here are the conclusions:1. The total assets have been increasing over the years, reaching $365,725,000,000 in 2018.
2. Current assets include cash, inventory, and receivables, with a significant portion in cash equivalents and short-term investments.
3. Non-current assets consist mainly of investments and advances, along with machinery, furniture, and equipment.
4. Total liabilities have also been increasing, but at a slower pace compared to assets, resulting in a growth in shareholders' equity.
5. Shareholders' equity includes common stock, retained earnings, and other equity components.
6. The company has been managing its short-term and long-term debts while investing in non-current assets for future growth.
7. The accumulated depreciation indicates the wear and tear on the company's assets over the years.
8. The provision for risks and charges has been relatively stable across the years.
9. The company has been maintaining a healthy balance between its assets, liabilities, and shareholders' equity.
Cash Flow 💶
This is the cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value in 2022 and the lowest in 2020.
2. Operating cash flow has generally been increasing, indicating improved operational efficiency.
3. The company has been consistently paying interest and income taxes, with varying amounts each year.
4. The end cash position has also been fluctuating, reaching its highest value in 2020.
5. Financing activities show significant changes each year, with large amounts being spent on common stock repurchase and debt issuance.
6. Investing activities also vary, with significant amounts being spent on the sale and purchase of investments, as well as capital expenditures.
7. Overall, the company's financial activities show a mix of strategies aimed at managing cash flow, debt, and investments.
Earnings estimate
Based on the analysts' estimates for future quarterly and annual earnings per share (EPS), we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average EPS estimate is $1.23, with a low estimate of $1.18 and a high estimate of $1.26. Compared to the EPS of $1.17 from a year ago, there is expected growth.
2. For the next quarter ending on September 30, 2024, the average EPS estimate is $1.42, with a low estimate of $1.33 and a high estimate of $1.51. This also shows an increase from the EPS of $1.35 reported a year ago.
3. Looking at the estimates for the current fiscal year ending on September 30, 2024, analysts project an average EPS of $6.10, ranging from $5.95 to $6.41. This indicates growth compared to the EPS of $5.67 for the previous year.
4. For the next fiscal year ending on September 30, 2025, the average EPS estimate is $6.69, with a low estimate of $5.92 and a high estimate of $7.31. This forecast suggests further growth from the expected EPS of $6.10 for the current fiscal year.
Overall, the analysts' estimates point towards a positive outlook with expected earnings growth in both the short term and the long term.
Revenue estimate
The analysts' estimates for the future quarterly and annual sales of the company indicate a moderate growth trend.For the current quarter ending on June 30, 2024, the average estimate is $77,545,400,000, representing a 2% increase from the same period last year. The number of analysts providing estimates is 25.
Looking at the next quarter ending on September 30, 2024, the average estimate is $85,501,800,000, with a sales growth of 3% compared to the previous year. Again, 25 analysts have contributed to these estimates.
For the current fiscal year ending on September 30, 2024, the average estimate is $357,772,000,000, showing a 1% growth from the previous year. The number of analysts providing estimates for the annual sales is 38.
In the following fiscal year ending on September 30, 2025, the average estimate is $380,772,000,000, indicating a more significant growth of 6% from the current fiscal year. The number of analysts remains at 38.
Overall, the estimates suggest a steady growth trajectory for the company's sales in both the short term and the long term.
Growth estimates
Based on the consensus estimates provided, we can draw the following conclusions regarding the growth rate of the company for different periods:1. Current Quarter: The estimated growth rate for the current quarter is 5.6%.
2. Next Quarter: The estimated growth rate for the next quarter is 4.8%.
3. Current Year: The estimated growth rate for the current year is 7.5%.
4. Next Year: The estimated growth rate for the next year is 9.7%.
5. Past 5 Years (per annum): The average growth rate for the past 5 years is 20.1%.
6. Next 5 Years (per annum): The estimated growth rate for the next 5 years is 11%.
These estimates suggest a positive growth trend for the company, with a slightly lower growth rate expected in the next 5 years compared to the past 5 years. The company is projected to experience steady growth in the short term, with a significant increase in growth rate expected for the next year.
Price target
Based on the analysts' forecast, the future price of the security is expected to range between $164 (low) and $250 (high), with a median estimate of $200 and an average estimate of $202.26. The current price of the security is $191.57.MACD of 4967
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
